ASCO: Fewer Toxicities With Weekly Adjuvant Paclitaxel in Breast Cancer

A phase III trial presented at ASCO showed similar efficacy between two adjuvant paclitaxel regimens, but the weekly regimen led to fewer patient side effects.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news